Filtered By:
Drug: Fortamet
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 8614 results found since Jan 2013.
Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients
CONCLUSION: Both metformin hydrochloride/vildagliptin and liraglutide have good therapeutic effects on T2DM in obese patients and can achieve good blood glucose and weight control, but liraglutide has a better effect for weight control.PMID:37087589 | PMC:PMC10122729 | DOI:10.12122/j.issn.1673-4254.2023.03.14
Source: Journal of Southern Medical University - April 23, 2023 Category: Universities & Medical Training Authors: B Zhou J Li C Fang Y Huang G Sang S Tao C He Source Type: research
Pharmacological management of obese child
Childhood overweight and obesity are increasingly common management problems for clinicians. This review focuses on the pharmacological management of obesity in children. It considers historical treatments, the options currently available (principally orlistat and metformin) and some potential future therapeutic interventions. The short term psychological effect of obesity and longer term health impact are discussed. The clinical settings in which drug treatment may be appropriate, the importance of lifestyle interventions, and the evidence and clinical guidance that underpin their use are discussed.
Source: Archives of Disease in Childhood - Education and Practice - May 13, 2013 Category: Pediatrics Authors: Petkar, R., Wright, N. Tags: Obesity (nutrition), Child health, Health education, Obesity (public health), Health promotion Pharmacy update Source Type: research
Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)
Swiss Med Wkly. 2023 Apr 1;153:40060. doi: 10.57187/smw.2023.40060.ABSTRACTAs a first step, the authors emphasise lifestyle changes (increased physical activity, stopping smoking), blood pressure control, and lowering cholesterol). The initial medical treatment should always be a combination treatment with metformin and a sodium-glucose transporter 2 (SGLT-2) inhibitor or a glucagon-like 1 peptide (GLP-1) receptor agonist. Metformin is given first and up-titrated, followed by SGLT-2 inhibitors or GLP-1 receptor agonists. In persons with type 2 diabetes, if the initial double combination is not sufficient, a triple combinat...
Source: Swiss Medical Weekly - April 3, 2023 Category: General Medicine Authors: Giacomo Gastaldi Barbara Lucchini Sebastien Thalmann Stephanie Alder Markus Laimer Michael Br ändle Peter Wiesli Roger Lehmann Working group of the SGED/SSED Source Type: research
The Top 7 Tox Articles of 2013
As we celebrate the year just ending, and welcome in 2014, let’s pause and remember some of the articles in the field of medical toxicology that most impressed TPR during 2013. The following 7 papers are listed in chronological order (links connect to TPR‘s discussion of each article):
Pediatric Marijuana Exposures in a Medical Marijuana State. Wang GS et al. JAMA Pediatr 2013 July;167:630-3 With several states legalizing recreational marijuana — and many more allowing medical marijuana — cases of inadvertent pediatric exposure to cannabis will undoubtedly increase, and it is important for emergency practi...
Source: The Poison Review - December 31, 2013 Category: Toxicology Authors: Leon Tags: Medical 2013 medical toxicology top articles Source Type: news
Analysis of treatment pathways for three chronic diseases using OMOP CDM
AbstractThe present study examined treatment pathways (the ordered sequence of medications that a patient is prescribed) for three chronic diseases (hypertension, type 2 diabetes, and depression), compared the pathways with recommendations from guidelines, discussed differences and standardization of medications in different medical institutions, explored population diversification and changes of clinical treatment, and provided clinical big data analysis-based data support for the development and study of drugs in China. In order to run the “Treatment Pathways in Chronic Disease” protocol in Chinese data sources,we ha...
Source: Journal of Medical Systems - November 13, 2018 Category: Information Technology Source Type: research
Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide
CONCLUSIONS: Obesity and antidiabetic drugs caused sex-related differences in the level of antioxidative parameters. Liraglutide exhibited stronger antioxidative effects than metformin. These results indicate that weight gain due to HSHFD is crucial for developing oxidative stress and for inhibiting antioxidative protective mechanisms.PMID:34212558 | PMC:PMC8275945 | DOI:10.3325/cmj.2021.62.215
Source: Croatian Medical Journal - July 2, 2021 Category: General Medicine Authors: Anita Mati ć Rosemary Vukovi ć Marija Heffer Marta Balog Vedrana Ivi ć Robert Gaspar Eszter Ducza Kalman F Szucs Adrienn Seres Sandor G Vari Ines Drenjan čević Source Type: research
